NCT00834444 is a Phase 1 clinical trial of Famciclovir 500 mg Tablets in Healthy, sponsored by Teva Pharmaceuticals USA.

Who is sponsoring NCT00834444?

NCT00834444 is sponsored by Teva Pharmaceuticals USA.

What drugs are being tested in NCT00834444?

Interventions in NCT00834444: Famciclovir 500 mg Tablets, Famvir® 500 mg Tablets.

Is NCT00834444 still recruiting?

NCT00834444 is currently completed. Last updated 16 August 2024.

Are results published for NCT00834444?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-08-16 · How we verify

NCT00834444

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single Dose, Comparative Bioavailability Study of Two Formulations of Famciclovir 500 mg Tablets Under Non-Fasting Conditions

Completed Phase 1 Results posted Last updated 16 August 2024

What this trial tests

Phase 1 trial testing Famciclovir 500 mg Tablets in Healthy in 36 participants. Completed in 1 September 2004.

Timeline

1 August 2004

Primary endpoint
1 September 2004

1 September 2004

Quick facts

Lead sponsor	Teva Pharmaceuticals USA
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	36
Start date	1 August 2004
Primary completion	1 September 2004
Estimated completion	1 September 2004
Sites	2 locations across United States, Canada

Drugs / interventions tested

Famciclovir 500 mg Tablets — full drug profile →
Famvir® 500 mg Tablets — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Teva Pharmaceuticals USA — full company profile →

Who can join

18 and older, any sex, with Healthy. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Cmax = Maximum Observed Concentration.
Time frame: Blood samples collected over a 16 hour period.
Bioequivalence based on Cmax.
AUC0-t = Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (Per Participant)
Time frame: Blood samples collected over a 16 hour period.
Bioequivalence based on AUC0-t.
AUC0-inf = Area Under the Concentration-time Curve From Time Zero to Infinity.
Time frame: Blood samples collected over a 16 hour period.
Bioequivalence based on AUC0-inf.

Sponsor's own description

The objective of this study is to compare the relative bioavailability of famciclovir 500 mg tablets (Novopharm Limited) with that of FAMVIR® 500 mg tablets (Novartis) in healthy adult subjects under non-fasting conditions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Teva Pharmaceuticals USA trials

Trials by the same sponsor.

NCT06742957 — Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis · Phase 3 · completed
NCT05617820 — Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspare · Phase 3 · completed
NCT05550337 — Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris · Phase 3 · completed
NCT04976192 — Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria · Phase 3 · completed
NCT04729621 — A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00834444 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Teva Pharmaceuticals USA
Last refreshed: 16 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00834444.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing